This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain CI
Evolus, Inc. Announces Positive Data from Pivotal Trial for First Two Evolysse? Dermal Filler Products at 2024 SCALE Meeting CI
Certain Options of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024. CI
Certain Common Stock of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024. CI
Certain Restricted Stock Units of Evolus, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2024. CI
Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : Evolus, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (EOLS) EVOLUS Reports Q1 Revenue $59.3M, vs. Street Est of $57.3M MT
Evolus, Inc. Reaffirms Financial Guidance for the Full Year 2024 CI
AbbVie raises annual profit forecast on strong Skyrizi sales RE
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau CI
Evolus, Inc. Announces Board Changes CI
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing MT
Transcript : Evolus, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Evolus Prices $50 Million Share Offering MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating MT
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours MT
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Evolus, Inc., Q4 2023 Earnings Call, Mar 07, 2024
Earnings Flash (EOLS) EVOLUS Posts Q4 Revenue $61M, vs. Street Est of $61.1M MT
Evolus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals RE
North American Morning Briefing : Microsoft Kicks -2- DJ
Chart Evolus, Inc.
More charts
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.64 USD
Average target price
22.29 USD
Spread / Average Target
+109.45%
Consensus
  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. News Evolus, Inc.
  5. Evolus Names Sandra Beaver Chief Financial Officer